Lee's Pharmaceutical Holdings Limited (FRA:L1PA)

Germany · Delayed Price · Currency is EUR

0.1120

-0.0010 (-0.88%)

Last updated: Oct 23, 2026, 3:25 PM CEST

Market Cap	73.09M -43.7%
Revenue (ttm)	171.63M +7.1%
Net Income	13.37M +22.5%
EPS	0.02 +22.4%
Shares Out	n/a
PE Ratio	4.84
Forward PE	n/a
Dividend	0.01 (5.77%)
Ex-Dividend Date	Sep 25, 2026

Volume	6
Open	0.1140
Previous Close	0.1130
Day's Range	0.1120 - 0.1140
52-Week Range	0.1040 - 0.2080
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 25, 2026

About FRA:L1PA

Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as cardiovascular, woman’s health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates in Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells Nadroparin Calcium injection and Livaracine to trea... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1994

Employees 1,137

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol L1PA

Financial Performance

In 2025, FRA:L1PA's revenue was 1.44 billion, an increase of 2.57% compared to the previous year's 1.40 billion. Earnings were 91.94 million, a decrease of -1.25%.

Financial numbers in HKD Financial Statements